Subscribe here to receive updates, including stories like these, via email. Or if you have your own blood cancer story to share, we’d love to hear from you.
Patients understand that clinical best practice care begins with an accurate and timely diagnosis.
For the third time, selinexor (Xpovio®) will be considered by the Pharmaceutical Benefits Advisory Committee (PBAC) at its November 2022 meeting for the treatment of relapsed/refractory (R/R) myeloma.
During the 22 years Martin Boling has had myeloma, blood cancer of various types has affected four other members of his family too, not just him.
Meet the research team developing a myeloma treatment with maximum efficacy and minimal side effects
